228 related articles for article (PubMed ID: 31747137)
41. Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021.
Tapia JC; Bosma F; Gavira J; Sanchez S; Molina MA; Sanz-Beltran J; Martin-Lorente C; Anguera G; Maroto P
Clin Genitourin Cancer; 2024 Jun; 22(3):102047. PubMed ID: 38430859
[TBL] [Abstract][Full Text] [Related]
42. Sarcoid-like reactions to immune checkpoint inhibitors: Incidence, treatment course, and impact on cancer progression and survival.
Smith H; Easterling R; Ma J; Moodabagil M; Meara A; Owen DH; Crouser E; Singha A; Ho K
Respir Med; 2024 Jun; 227():107640. PubMed ID: 38648910
[TBL] [Abstract][Full Text] [Related]
43. Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer.
Zeng Y; Hu CH; Li YZ; Zhou JS; Wang SX; Liu MD; Qiu ZH; Deng C; Ma F; Xia CF; Liang F; Peng YR; Liang AX; Shi SH; Yao SJ; Liu JQ; Xiao WJ; Lin XQ; Tian XY; Zhang YZ; Tian ZY; Zou JA; Li YS; Xiao CY; Xu T; Zhang XJ; Wang XP; Liu XL; Wu F
Nat Med; 2024 Jun; 30(6):1680-1688. PubMed ID: 38740994
[TBL] [Abstract][Full Text] [Related]
44. Impact of concurrent medications on the outcome of immunotherapy in non-small cell lung carcinoma.
Yamada J; Fukui T; Yatani A; Mimura C; Fukuda K; Hazama D; Katsurada N; Nagano T; Yamamoto M; Tachihara M
Thorac Cancer; 2024 May; 15(15):1228-1236. PubMed ID: 38622898
[TBL] [Abstract][Full Text] [Related]
45. Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry.
Ma W; Wei S; Long S; Tian EC; McLaughlin B; Jaimes M; Montoya DJ; Viswanath VR; Chien J; Zhang Q; Van Dyke JE; Chen S; Li T
Front Immunol; 2023; 14():1206631. PubMed ID: 37638022
[TBL] [Abstract][Full Text] [Related]
46. Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).
Dehem A; Mazieres J; Chour A; Guisier F; Ferreira M; Boussageon M; Girard N; Moro-Sibilot D; Cadranel J; Zalcman G; Ricordel C; Wislez M; Munck C; Poulet C; Gauvain C; Descarpentries C; Wasielewski E; Cortot AB; Baldacci S
Lung Cancer; 2023 Dec; 186():107393. PubMed ID: 37839252
[TBL] [Abstract][Full Text] [Related]
47. Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Mogenet A; Finetti P; Denicolai E; Greillier L; Boudou-Rouquette P; Goldwasser F; Lumet G; Ceccarelli M; Birnbaum D; Bedognetti D; Mamessier E; Barlesi F; Bertucci F; Tomasini P
J Transl Med; 2023 Sep; 21(1):637. PubMed ID: 37726776
[TBL] [Abstract][Full Text] [Related]
48. Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
Yamaguchi O; Mori K; Takata S; Shibata K; Chikamori K; Kimura N; Nagai Y; Nakagawa T; Igawa S; Harada T; Yoshioka H; Tanaka H; Nogawa H; Satoh H; Shiozawa T; Tsuji K; Kobayashi K; Kaira K
Thorac Cancer; 2024 Jan; 15(2):163-171. PubMed ID: 38013668
[TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of CT-determined sarcopenia in older patients with advanced squamous cell lung cancer treated with programmed death-1 inhibitors.
Ying L; Xu L; Yang J; Zhang Q
Sci Rep; 2024 May; 14(1):12025. PubMed ID: 38797769
[TBL] [Abstract][Full Text] [Related]
50. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
Djunadi TA; Oh Y; Lee J; Yu J; Chung LI; Lee Y; Kim L; Hong T; Lee S; Shah Z; Park JH; Yoon SM; Chae YK
Clin Lung Cancer; 2024 Jun; 25(4):365-375.e14. PubMed ID: 38644088
[TBL] [Abstract][Full Text] [Related]
51. Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis.
Hu Y; Liu S; Wang L; Liu Y; Zhang D; Zhao Y
Front Immunol; 2023; 14():1202822. PubMed ID: 37520573
[TBL] [Abstract][Full Text] [Related]
52. [Advances in Pseudoprogression of Immune Checkpoint Inhibitors
in Non-small Cell Lung Cancer].
Tong Y; Long Y; Zhang F; Li J
Zhongguo Fei Ai Za Zhi; 2024 Apr; 27(4):306-320. PubMed ID: 38769834
[TBL] [Abstract][Full Text] [Related]
53. Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings.
Zu K; Arunachalam A; Hohlbauch A; Silver M; Robert N
Immunotherapy; 2023 Nov; 15(16):1375-1387. PubMed ID: 37694560
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer.
Xu M; Hao Y; Shi Z; Song Z
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17987-17995. PubMed ID: 37975902
[TBL] [Abstract][Full Text] [Related]
55. NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis.
Tang W; Li C; Huang D; Zhou S; Zheng H; Wang Q; Zhang X; Fu J
Cancer Biol Ther; 2024 Dec; 25(1):2358551. PubMed ID: 38813753
[TBL] [Abstract][Full Text] [Related]
56. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors.
Yamauchi T; Hoki T; Oba T; Jain V; Chen H; Attwood K; Battaglia S; George S; Chatta G; Puzanov I; Morrison C; Odunsi K; Segal BH; Dy GK; Ernstoff MS; Ito F
Nat Commun; 2021 Mar; 12(1):1402. PubMed ID: 33658501
[TBL] [Abstract][Full Text] [Related]
57. 5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer.
Shao J; Xu Y; Olsen RJ; Kasparian S; Sun K; Mathur S; Zhang J; He C; Chen SH; Bernicker EH; Li Z
Cells; 2024 Apr; 13(8):. PubMed ID: 38667328
[TBL] [Abstract][Full Text] [Related]
58. Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takeuchi E; Kondo K; Okano Y; Ichihara S; Kunishige M; Kadota N; Machida H; Hatakeyama N; Naruse K; Ogino H; Nokihara H; Shinohara T; Nishioka Y
Thorac Cancer; 2023 Oct; 14(30):3042-3050. PubMed ID: 37669914
[TBL] [Abstract][Full Text] [Related]
59. Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Young P; Elghawy O; Mock J; Wynter E; Gentzler RD; Martin LW; Novicoff W; Hall R
Curr Oncol; 2024 Jan; 31(1):260-273. PubMed ID: 38248102
[TBL] [Abstract][Full Text] [Related]
60. Correlation between changes in nutritional status and tumor response in patients receiving immunotherapy for lung cancer (NUTIMMUNO study).
Mahé M; Seegers V; Vansteene D
Support Care Cancer; 2024 Apr; 32(5):312. PubMed ID: 38676729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
